A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Status:
Recruiting
Trial end date:
2024-11-06
Target enrollment:
Participant gender:
Summary
This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to
evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102
(biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.